vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and NATURAL RESOURCE PARTNERS LP (NRP). Click either name above to swap in a different company.

NATURAL RESOURCE PARTNERS LP is the larger business by last-quarter revenue ($51.3M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). NATURAL RESOURCE PARTNERS LP runs the higher net margin — 78.5% vs -161.8%, a 240.3% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -21.8%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Natural Resource Partners LP is a U.S.-headquartered master limited partnership that owns, manages and leases mineral reserve interests. Its asset portfolio covers coal, aggregates, industrial minerals and oil & gas, with operations primarily across North America, deriving most revenue from royalties paid by third-party resource extraction operators.

IBRX vs NRP — Head-to-Head

Bigger by revenue
NRP
NRP
1.3× larger
NRP
$51.3M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+428.8% gap
IBRX
407.0%
-21.8%
NRP
Higher net margin
NRP
NRP
240.3% more per $
NRP
78.5%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
IBRX
IBRX
NRP
NRP
Revenue
$38.3M
$51.3M
Net Profit
$-61.9M
$40.3M
Gross Margin
99.0%
Operating Margin
-169.0%
83.7%
Net Margin
-161.8%
78.5%
Revenue YoY
407.0%
-21.8%
Net Profit YoY
-4.7%
-28.4%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
NRP
NRP
Q4 25
$38.3M
Q3 25
$32.1M
Q2 25
$26.4M
Q1 25
$16.5M
$51.3M
Q4 24
$7.6M
$61.8M
Q3 24
$6.1M
$50.4M
Q2 24
$54.6M
Q1 24
$65.6M
Net Profit
IBRX
IBRX
NRP
NRP
Q4 25
$-61.9M
Q3 25
$-67.3M
Q2 25
$-92.6M
Q1 25
$-129.6M
$40.3M
Q4 24
$-59.2M
$42.8M
Q3 24
$-85.7M
$38.6M
Q2 24
$46.1M
Q1 24
$56.2M
Gross Margin
IBRX
IBRX
NRP
NRP
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
NRP
NRP
Q4 25
-169.0%
Q3 25
-173.5%
Q2 25
-269.8%
Q1 25
-390.1%
83.7%
Q4 24
-919.0%
74.9%
Q3 24
-1314.3%
84.9%
Q2 24
92.3%
Q1 24
91.0%
Net Margin
IBRX
IBRX
NRP
NRP
Q4 25
-161.8%
Q3 25
-209.8%
Q2 25
-350.3%
Q1 25
-784.9%
78.5%
Q4 24
-783.4%
69.2%
Q3 24
-1404.0%
76.6%
Q2 24
84.4%
Q1 24
85.7%
EPS (diluted)
IBRX
IBRX
NRP
NRP
Q4 25
$-0.06
Q3 25
$-0.07
Q2 25
$-0.10
Q1 25
$-0.15
Q4 24
$-0.08
Q3 24
$-0.14
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
NRP
NRP
Cash + ST InvestmentsLiquidity on hand
$242.8M
$30.9M
Total DebtLower is stronger
$138.8M
Stockholders' EquityBook value
$-500.5M
Total Assets
$501.9M
$772.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
NRP
NRP
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
$30.9M
Q4 24
$149.8M
$30.4M
Q3 24
$130.4M
$30.9M
Q2 24
$32.3M
Q1 24
$11.0M
Total Debt
IBRX
IBRX
NRP
NRP
Q4 25
Q3 25
Q2 25
Q1 25
$138.8M
Q4 24
$142.1M
Q3 24
$197.4M
Q2 24
$210.3M
Q1 24
$188.8M
Stockholders' Equity
IBRX
IBRX
NRP
NRP
Q4 25
$-500.5M
Q3 25
$-524.3M
Q2 25
$-570.7M
Q1 25
$-591.4M
Q4 24
$-489.1M
Q3 24
$-745.1M
Q2 24
Q1 24
Total Assets
IBRX
IBRX
NRP
NRP
Q4 25
$501.9M
Q3 25
$519.0M
Q2 25
$402.1M
Q1 25
$303.8M
$772.5M
Q4 24
$382.9M
$772.9M
Q3 24
$364.6M
$772.9M
Q2 24
$789.6M
Q1 24
$772.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
NRP
NRP
Operating Cash FlowLast quarter
$-70.4M
$34.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
0.86×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
NRP
NRP
Q4 25
$-70.4M
Q3 25
$-68.9M
Q2 25
$-79.7M
Q1 25
$-85.9M
$34.4M
Q4 24
$-85.1M
$66.2M
Q3 24
$-98.8M
$54.1M
Q2 24
$56.6M
Q1 24
$71.5M
Free Cash Flow
IBRX
IBRX
NRP
NRP
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
NRP
NRP
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
NRP
NRP
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
0.0%
Q3 24
45.7%
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
IBRX
IBRX
NRP
NRP
Q4 25
Q3 25
Q2 25
Q1 25
0.86×
Q4 24
1.55×
Q3 24
1.40×
Q2 24
1.23×
Q1 24
1.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

NRP
NRP

Coal Royalty Revenues$35.5M69%
Soda Ash Segment$4.6M9%
Transportation And Processing Services$4.4M9%
Production Lease Minimum Revenues$2.7M5%
Oil And Gas Royalty Revenues$2.4M5%
Other$1.6M3%

Related Comparisons